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Background: All international guidelines recommend perioperative antibiotic prophylaxis (PAB) should be
routinely administered to patients undergoing cardiac surgery. However, the duration of PAB is heterogeneous
and controversial.
Methods: Between 01.01.2011 and 31.12.2011, 1096 consecutive cardiac surgery patients were assigned to one of
two groups receiving PAB with a second-generation cephalosporin for either 56 h (group I) or 32 h (group II). Patients’
characteristics, intraoperative data, and the in-hospital follow-up were analysed. Primary endpoint was the incidence of
surgical site infection (deep and superficial sternal wound-, and vein harvesting site infection; DSWI/SSWI/VHSI).
Secondary endpoints were the incidence of respiratory-, and urinary tract infection, as well as the mortality rate.
Results: 615/1096 patients (56,1%) were enrolled (group I: n = 283 versus group II: n = 332). There were no
significant differences with regard to patient characteristics, comorbidities, and procedure-related variables. No
statistically significant differences were demonstrated concerning primary and secondary endpoints. The incidence
of DSWI/SSWI/VHSI were 4/283 (1,4%), 5/283 (1,7%), and 1/283 (0,3%) in group I versus 6/332 (1,8%), 9/332 (2,7%),
and 3/332 (0,9%) in group II (p = 0,76/0,59/0,63). In univariate analyses female gender, age, peripheral arterial
obstructive disease, operating-time, ICU-duration, transfusion, and respiratory insufficiency were determinants for
nosocomial infections (all ≤ 0,05). Subgroup analyses of these high-risk patients did not show any differences
between the two regimes (all ≥ 0,05).
Conclusions: Reducing the duration of PAB from 56 h to 32 h in adult cardiac surgery patients was not associated
with an increase of nosocomial infection rate, but contributes to reduce antibiotic resistance and health care costs.
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The principles of antibiotic prophylaxis are based on (1)
the choice of the antimicrobial agent; (2) the timing of
the first administered dose, and (3) the duration of the
prophylactic regimen [1]. Concerning the choice of the
antimicrobial agent second-generation cephalosporins in
particular have several advantages over other antibiotic
choices. They provide broad-spectrum coverage target-
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unless otherwise stated.with good tissue penetration. Furthermore, they have a
good safety profile with minimal side effects, and can be
tolerated by penicillin allergic patients. However, a dis-
advantage of cephalosporins is a well-established associ-
ation with Clostridium difficile infection [2]. Several
studies described that there is a trend towards prescrib-
ing more second generation cephalosporins [3,4]. Also,
the German Paul-Ehrlich-Gesellschaft e.V. (PEG) recom-
mends a second-generation cephalosporin as antibiotic
prophylaxis in patients undergoing cardiac surgery [5].
Concerning the duration of the prophylactic regimen
the data of the international guidelines and recommen-
dations of antibiotic prophylaxis in adult cardiac surgeryral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of Cardiology Foundation/American Heart Association
guideline for coronary artery bypass graft surgery recom-
mends preoperative antibiotic prophylaxis with additional
application for prolonged operations [6,7]. Even the rec-
ommendation from the PEG concerning the duration is
based only on consensus of the expert panel because the
data do not delineate the optimal duration of prophylaxis.
The panel suggests the prophylaxis for 24 hours or less as
appropriate for cardiothoracic procedures [5]. There is no
common recommendation of single dose administration
or for longer than a 48-hour regimen. Gorski et al. dem-
onstrated in a nationwide questionnaire was distributed to
all German heart surgery centers concerning antibiotic
prophylaxis in adult cardiac surgery patients that 100% of
all German heart centers use an antibiotic prophylaxis [8].
But the duration strategy of antibiotic prophylaxis in adult
cardiac surgery patients varied wildly. 23% use a single-
shot prophylaxis, 29% use it for 16 hours, 27% use it for
24 hours, 13% use it for 32 hours, and still 8% use it for
40 hours [8].
Most guidelines suggest that prophylaxis for 48 hours
or less may be appropriate for cardiothoracic proce-
dures [1,5,6,9,10]. Table 1 shows an overview of the dif-
ferent international guidelines regarding the antibiotic
prophylaxis for cardiac surgery patients.
The incidence of nosocomial infections after cardiac
surgery is described with 2,7% [11] up to 26,8% [12] in
recent literature. They represent serious complications
associated with substantial morbidity and mortality as
well as economic burden [5,9,13-15]. Therefore, routine
administration of perioperative antibiotic prophylaxis in
cardiac surgery patients is well accepted, but the dur-
ation for which the antibiotics should be administered is
far from settled [2]. There has been a general move to-
wards the use of shorter courses of antibiotics for surgi-
cal prophylaxis in order to reduce toxicity, selection of
resistant organisms, Clostridium difficile infection and
cost [7]. The development of antibiotic-resistant infections
has been associated with significantly greater hospitalTable 1 Guidelines for the duration of antibiotic prophylaxis
Duration
STS There is evidence indicating that antibiotic prophylaxis of 48-h
prophylaxis or 24-hour prophylaxis may be as effective as 48-h
the effectiveness of prophylaxis lasting less than 48 hours. The
is more effective than a 48-hour regimen.
PEG The duration is based on consensus of the expert panel becau
Prophylaxis for 24 hours or less may be appropriate for cardio
SIPGWW The consensus of the workgroup is that administration of pro
providing antimicrobials for longer periods will reduce surgica
ACC/AHA Data suggest that a 1-day course of intravenous antimicrobial
ASHP Prophylaxis for 24 hours or less may be appropriate for cardio
STS The Society of Thoracic Surgeons, PEG Paul-Ehrlich-Gesellschaft e.V., SIPGWW Su
Society of Health-System Pharmacists Commission on Therapeutics.mortality rates compared to similar infections caused by
antibiotic-sensitive pathogens [16]. However, cardiac sur-
gery patients leave the operating room with indwelling
chest catheters and central venous and arterial lines that
can be potential routes for bacterial entry and increase the
risk of infection [2].
The purpose of this study was to evaluate the effect of
reducing the duration of perioperative antibiotic prophy-
laxis in adult cardiac surgery patients from 56 hours to a
32 hours use on the incidence of surgical site infections,
nosocomial infections, and the mortality rate.
Methods
Study design and patient population
This retrospective observational study analyses 1096 car-
diac surgical patients consecutively subjected to cardiac
surgery between 01.01.2011 and 31.12.201 at the University
Hospital Würzburg, Department of thoracic and cardiovas-
cular surgery. Inclusion criteria were defined as follows:
Male and female patient aged 18 years or older, heart sur-
gery procedure ± extracorporal circulation (coronary artery
bypass grafting ± valve surgery). Exclusion criteria were de-
fined as follows: preoperative signs of infection, history of
allergy to the antibiotic to be used in this study, transapical
or transfemoral aortic valve implantation, participation in
another clinical study. Each patient routinely received peri-
operative prophylaxis for a fixed period of time with i.v.
cefuroxime (1.5 g every 8 hours). Furthermore, all patients
were treated with the same glycemic control protocol. In
order to improve the quality of medical care we initially
reduced the perioperative antibiotic prophylaxis strategy
from 56 h towards 32 h duration. Therefore, the pa-
tients were divided into two groups according to the
timing of surgery. Group I included 283 patients from
01.01.2011 to 30.06.2011 who received 56 h of PAB and
group II included 332 patients from 01.07.2011 to
31.12.2011 who received 32 h of PAB. The preoperative,
intraoperative, and postoperative protocol for preventing
wound infections was not changed during the course of
this study.in cardiac surgery
ours duration is effective. There is some evidence that single-dose
our prophylaxis, but additional studies are necessary before confirming
re is no evidence that prophylaxis administered for longer than 48 hours
se the data do not delineate the optimal duration of prophylaxis.
thoracic procedures.
phylaxis for < 24 hours is acceptable and that there is no evidence that
l site infection rates.
s is as efficacious as the traditional 48-hour (or longer) regimen.
thoracic procedures.
rgical Infection Prevention Guideline Writers Workgroup, ASHP American
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Medical records were checked for demographic, preopera-
tive, intraoperative and postoperative data and complica-
tions. Because of the retrospective design of this study, an
ethics votum or signed informed consent was waived.
Data were processed and analysed respecting every pa-
tient’s anonymity. The corresponding author had full ac-
cess to all data and had final responsibility for the decision
to submit for publication.
Definition of study variables and End points
All patients were examined once daily up to the time of
discharge for wound healing and signs of infection by
the treating physicians within the routine clinical course.
Preoperatively and on postoperative days 1, 2, 4, and 7
and on the day before discharge, the leucocyte count
and C-reactive protein (CRP) were determined. If infec-
tion was suspected, these parameters were additionally
measured on an ad hoc basis. Surgical wound infection
(deep,- and superficial sternal wound infection and vein
harvesting site infection), respiratory tract infection, and
urinary tract infection were defined according to the
guidelines published by the Centers for Disease Control
and Prevention [11,17]. Sepsis was defined as the pres-
ence of whole body inflammatory state in the presence
of a known or suspected infection [5,18,19]. Primary
endpoint was the development of microbiologically doc-
umented surgical site infection (SSI), like deep sternal
wound infection (DSWI), superficial sternal wound in-
fection (SSWI) and vein harvesting site infection (VHSI).
Secondary endpoints were the occurrence of nosocomial
infection (respiratory tract infection and urinary tract in-
fection) as well as the all-cause mortality rate, including
the infection and non-infection related mortality rate.
The follow-up time for all patients was until discharge.
The mortality was followed-up until 30 days postopera-
tively. If a patient was readmitted to hospital because of
a SSI, the data were involved in the analysis.
Statistical analysis
Statistical analysis was performed by an independent stat-
istician at the Institute of Mathematics and Informatics,
Chair of Mathematics VIII (Statistics), University of
Würzburg. The open source software R (version 2.12.1)
was used. A p value of ≤ 0,05 was deemed to be statisti-
cally significant. For ratio-scaled variables a descriptive
overview of the two groups (active drug vs. placebo) was
always prepared. The two groups were then analysed
with the Mann–Whitney U test for significant differences.
A group overview was also prepared for nominal-scaled
variables. To determine differences in these values, the
Chi-square test of independence was performed. If the
variable was binomial (e.g. gender) Fisher’s exact test was
applied and the odds ratio with a 95% confidence intervalwas calculated. The subgroup analysis was performed with
Fisher's exact test or the Mann–Whitney U test according
to the scale type of the corresponding measurement. For
all tests in the subgroup analysis the Benjamini-Hochberg
correction of the significance level was conducted. To
compare the two estimates of the two groups, a log-rank
test was done. The data were processed and analysed
while preserving the patient’s anonymity.
Results
615/1096 (56,1%) of the screened patients were included
in the study analysis. 481/1096 (43,9%) patients could
not be evaluated, because of the above mentioned inclu-
sion and/or exclusion criteria (Figure 1). 283/615 (46%)
patients were assigned to group I (56 h of PAB) and
332/615 (54%) to group II (32 h of PAB).
There were no significant differences with regard to pa-
tient characteristics, comorbidities, and procedure-related
variables (Table 2).
Regarding every single microbiological documented in-
fection 97 hits could be found in 615 patients (15,8%).
The incidence of deep sternal wound infection, superficial
sternal wound infection, and vein harvesting site infection
were 4/283 (1,4%), 5/283 (1,7%), and 1/283 (0,3%) in group
I versus 6/332 (1,8%), 9/332 (2,7%), and 3/332 (0,9%) in
group II (p = 0,76/0, 59/0,63), respectively. Also, no sta-
tistically significant differences were demonstrated con-
cerning secondary end-points. The all-cause mortality
after 30 days was 23/615 (3,7%) patients (group I, 2,4%
vs. group II, 4,8%, p = 0,14). The infection related mor-
tality rate was 2/283 (0,7%) patients in group I versus 4/
332 (1,2%) patients in group II (Table 3).
In this observational study, we were able to determine
why these patients were more likely to receive nosocomial
infections: female (p = 0,02), age > 80 years (p = 0,05), per-
ipheral arterial obstructive disease (p = 0,02), operating
time > 240 min (p = 0,01), ICU duration > 3 days (p = 0,01),
transfusion of > 5 RBC (p = 0,02), and respiratory insuffi-
ciency (p = 0,01) (Table 4).
Analysing these patients with an increased risk for
nosocomial infection relating to the two different anti-
biotic duration regimes (group I versus group II) no sta-
tistically significant difference could be demonstrated
(Table 5).
Discussion
The majority of published evidence in general surgery
demonstrates that antimicrobial prophylaxis after wound
closure is unnecessary, and most studies comparing single-
dose prophylaxis with multiple-dose prophylaxis have not
shown benefit of additional doses [10]. But there are sev-
eral reasons why prolonged (24 – 48 hours) prophylactic
regimens should be used in cardiac surgery, such as cardio-
pulmonary bypass and systemic cooling for myocardial
Cardiosurgical patients 
during the observation 
period (n = 1096)
Patients enrolled 
(n = 615)
Complete follow-up
(n = 615)
group I
n = 283
group II
n = 332
not enrolled n = 481:
No CABG or CABG ± valve; n = 344 
Preop. signs of infection, n = 12
History of allergy; n = 41
Transapical/Transfemoral valve; n = 63 
Participation in another trial; n = 21
Figure 1 Trial profile.
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risk of bleeding requiring blood transfusion and re-
exploration, and delayed extubation after surgery. Fur-
thermore, there are few data on the pharmacokinetics of
antibiotics during cardiopulmonary bypass, and there-
fore dosing regimens are often based on historical prac-
tice [7]. Besides these reasons, results from other trials
in cardiac surgery described that increasing the duration
of antibiotic prophylaxis in cardiac surgery patients did
not result in a significant decrease in surgical site infec-
tions [3,4,10,20-23]. Therefore, it is generally accepted
that short-term perioperative antibiotic prophylaxis is
as efficacious in preventing postoperative complications
as longer-term prophylaxis. However, the optimal dur-
ation of antibiotic prophylaxis in cardiac surgery is
controversial [21]. Recommendations for perioperative
antibiotic prophylaxis in cardiac surgery vary, ranging
from single infusion of antibiotics [3,22] to durations up
to 72 hours [21,24].
Comparison of single-versus multiple-dose perioperative
antibiotic prophylaxis
Nooyen et al. described in a prospective randomised com-
parison study (n = 844 patients) that a single dose of cefur-
oxime is as effective as a three-day course in the prevention
of wound infection (sternal site infection; p = 0,35 and
donor site infection; p = 0,41) [3]. This study showed many
exclusion criteria and the power of this study is too low to
draw any conclusion out of it. Even Bucknell et al. showed
in a non-randomized trial with 353 consecutive patients
that a single-dose antimicrobial prophylaxis (cefazolin) is aseffective as a 48-hour regimen. There was no significant
difference in rate of infection between the two groups
(p = 0,89) [22]. On the other hand, Tamayo et al. showed
in a random, prospective, clinical study included 838 adult
patients that single-dose-cefazolin is associated with a
higher surgical site infection rate than the 24 hour
multiple-dose cefazolin regimen (8,3% vs 3,6%; p = 0,00)
[25]. The follow-up period of this study was 12 months
postoperatively, the follow-up period of the studies
mentioned above by Nooyen et al. and Bucknell et al.
evaluated the sternal site infection only over 7 postoper-
ative days. This limitation is important because it is well
known that sternal infections usually manifest them-
selves from the second postoperative week onward [23].
Comparison of different multiple-dose perioperative
antibiotic prophylaxis
The results of the present study support the conclusion of
Gupta et al. [2]. They compared 235 adult patients under-
going elective cardiac surgery in a randomized double
blind study. The groups received prophylactic antibiotic
therapy for either 48 hours or 72 hours. The results
showed that 48 hours prophylactic antibiotic therapy is at
least as effective as a 72 hours regimen in relation to sur-
gical site infection (p > 0,05), but prevents the potential of
causing an increase in antibiotic resistance [24]. Further-
more, the literature contains 2 meta-analysis on patients
undergoing cardiac surgery and the duration of periopera-
tive antibiotic prophylaxis [21,26]. The first meta-analysis
by Mertz et al. included 7893 patients (including 12 stud-
ies) focusing on the risk of sternal surgical site infections
Table 2 Patient characteristics, comorbidities, and
procedure-related variables
All Group I Group II p-value
n = 615 n = 283 n = 332
Sex 0,85
• Men; n (%) 464 (75,4) 215 (75,9) 249 (75)
• Female; n (%) 151 (24,6) 68 (24,1) 83 (25)
Age (years) 68,7 ± 9,8 69,2 ± 9,7 68,3 ± 9,9 0,27
BMI (kg/m2) 28,3 ± 4,2 28,3 ± 4,0 28,3 ± 4,4 0,80
Diabetes mellitus; n (%) 181 (29,4) 88 (31) 93 (28) 0,89
COPD; n (%) 82 (13,3) 34 (12) 48 (14,4) 0,22
PAOD; n (%) 61 (9,9) 23 (8,1) 38 (11,4) 0,18
Creatinine (mg/dL) 1,0 ± 0,3 1,0 ± 0,2 1,0 ± 0,3 0,44
Dialyse; n (%) 13 (2,1) 7 (2,4) 6 (1,8) 0,59
EF < 30%; n (%) 53 (8,6) 23 (8,1) 30 (9,0) 0,93
Resucitation 0,60
• No; n (%) 592 (96,2) 275 (97,1) 317 (95,4)
• <48 h 13 (2,1) 4 (1,4) 9 (2,7)
• <21 days 9 (1,4) 4 (1,4) 5 (1,5)
• >21 days 1 (0,1) 0 (0) 0 (0)
PMV; n (%) 10 (1,6) 5 (1,7) 5 (1,5) 1,00
IABP preoperative; n (%) 111 (18) 46 (16,2) 65 (19,5) 0,30
State of operation; n (%) 0,79
• Elective 416 (67,6) 197 (69,6) 219 (65,9)
• Urgent 138 (22,4) 59 (20,8) 79 (23,7)
• Emergency 53 (8,6) 23 (8,1) 30 (9,0)
• Resuscitation 8 (1,3) 4 (1,4) 4 (1,2)
Type of procedure; n (%) 0,30
• isolated CABG 550 (89,4) 249 (87,9) 301 (90,6)
• CABG ± valve surgery 65 (10,6) 34 (12,1) 31 (9,4)
Procedure related variables
• Operating time (min) 218 ± 55 219 ± 58 218 ± 53 0,88
• Bypass time (min) 95 ± 32 97 ± 34 94 ± 30 0,49
• Clamping time (min) 69 ± 25 70 ± 26 68 ± 24 0,38
OPCAB; n (%) 36 (5,8) 18 (6,3) 18 (5,4) 0,41
ICU duration (days) 2,9 ± 2,6 2,9 ± 2,5 3,0 ± 2,6 0,66
Mobilisation; n (%) 0,44
1. pod 116 (18,8) 51 (18,0) 65 (19,5)
2. pod 255 (41,4) 130 (45,9) 125 (37,6)
3. pod 178 (28,9) 79 (27,9) 99 (29,8)
Not mobilized 30 (10,9) 13 (8,2) 17 (12,9)
Transfusion of RBC (n) 1,5 ± 3,3 1,5 ± 3,1 1,5 ± 3,6 0,87
Resuscitation; n (%) 21 (3,4) 10 (3,5) 11 (3,3) 1,00
Reintubation; n (%) 32 (5,2) 16 (5,6) 16 (4,8) 0,70
• Tracheotomy 5 (0,8) 2 (0,7) 3 (0,9)
Table 2 Patient characteristics, comorbidities, and
procedure-related variables (Continued)
TPS; n (%) 26 (4,2) 13 (4,5) 13 (3,9) 0,92
Revision; n (%) 38 (6,1) 21 (7,4) 17 (5,1) 0,18
Periop. MI; n (%) 5 (0,8) 1 (0,3) 4 (1,2) 0,38
BMI Body Mass Index, COPD chronic obstructive pulmonary disease, PAOD
peripheral arterial obstructive disease, EF ejection fraction, PMV preoperative
mechanical ventilation, IABP intraaortic balloon pulsation, CABG coronary
artery bypass grafting, OPCAB off-pump coronary artery bypass, ICU intensive
care unit, pod postoperative day, RBC red blood concentrate, TPS transitory
psychotic syndrome, Periop. MI perioperative myocardial infarction.
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versus longer-term antibiotic prophylaxis (≥24 hours)
among adult patients undergoing open heart surgery.
The authors found a reduced risk of sternal surgical site
infection by 38% (p = 0,01) in patients with longer-term
antibiotic prophylaxis. Therefore, they concluded that
antibiotic prophylaxis of > 24 hours may be more effica-
cious in preventing sternal SSIs compared to shorter
regimens. Similar to our results these studies do not
found any significant differences in mortality and overall
rate of infection. The findings however are limited by
the heterogeneity of antibiotic regimens used and the
risk of bias in the published studies [21]. The second study
published on this topic was carried out by Lador et al.
They reported of 23 randomized controlled trials and
stated that in trials comparing different durations, prophy-
laxis of≤ 24 h post-operation led to higher rates of DSWI,
any sternal SSI, surgical interventions for SSI and endocar-
ditis compared with longer duration prophylaxis. But there
was no advantage of regimens lasting> 48 hours post-
operation. However, the authors indicate that prolonging
prophylaxis include the induction of resistant bacteria
that may affect the individual patient and surroundingTable 3 Primary and secondary endpoints
All Group I Group II p-value
n = 615 n = 283 n = 332
Primary endpoints
DSWI; n (%) 10 (1,6) 4 (1,4) 6 (1,8) 0,76
SSWI; n (%) 14 (2,2) 5 (1,7) 9 (2,7) 0,59
VHSI; n (%) 4 (0,6) 1 (0,3) 3 (0,9) 0,63
Secondary endpoints
Respiratory tract infection;
n (%)
23 (3,7) 12 (4,2) 11 (3,3) 0,67
Urinary tract infection; n (%) 46 (7,4) 26 (9,1) 20 (6,0) 0,17
All-cause mortality; n (%) 23 (3,7) 7 (2,4) 16 (4,8) 0,14
• Mortality due to
infection
6 (0,98) 2 (0,71) 4 (1,20)
• Mortality due to other
cause
17 (2,76) 6 (2,12) 11 (3,31)
DSWI deep sternal wound infection, SSWI superficial sternal wound infection,
VHSI vein harvesting site infection.
Table 4 Univariate analyses
Infection No-Infection p-value
Sex; n (%) 0,02
• Men 58 (12,5) 406 (87,5)
• Female 31 (20,5) 120 (79,5)
Age; n (%) 0,05
• >80 years 18 (23,7) 58 (76,3)
• <80 years 71 (13,2) 468 (86,8)
BMI; n (%) 0,25
• >30 kg/m2 26 (13,8) 162 (86,2)
• <30 kg/m2 63 (14,8) 364 (85,2)
Diabetes mellitus; n (%) 0,33
• Yes 32 (17,1) 149 (82,3)
• No 57 (13,2) 377 (86,9)
PAOD; n (%) 0,02
• Yes 38 (19,3) 159 (80,7)
• No 12,2 (51) 367 (87,8)
COPD; n (%) 0,17
• Yes 17 (20,7) 65 (79,3)
• No 72 (13,5) 461 (86,5)
Dialyse; n (%) 1,00
• Yes 2 (15,4) 11 (84,6)
• No 87 (14,5) 515 (85,5)
State of operation; n (%) 0,82
• Elective 63 (15,1) 353 (84,9)
• Urgent 17 (12,3) 121 (87,7)
• Emergency 8 (15,1) 45 (84,9)
• Resuscitation 1 (12,5) 7 (87,5)
Operating time; n (%) 0,01
• >240 min 43 (20,6) 166 (79,4)
• <240 min 47 (11,3) 360 (88,7)
Bypass time; n (%) 0,16
• >90 min 51 (16,7) 254 (83,3)
• <90 min 31 (11,2) 246 (88,8)
Clamping time; n (%) 0,51
• >60 min 55 (15,5) 299 (84,5)
• <60 min 25 (11,8) 186 (88,2)
IABP postoperative; n (%) 0,23
• Yes 9 (14,8) 52 (85,2)
• No 80 (14,4) 474 (85,6)
ICU duration; n (%) 0,01
• <3 days 36 (10,5) 309 (89,6)
• >3 days 53 (19,7) 217 (80,4)
Table 4 Univariate analyses (Continued)
Perioperative MI; n (%) 0,64
• Yes 0 (0) 5 (100)
• No 89 (14,5) 521 (85,4)
IABP; n (%) 0,23
• Yes 9 (14,8) 52 (85,2)
• No 80 (14,4) 474 (85,6)
Transfusion of > 5 RBC; n (%) 0,02
• Yes 2,8 (23) 70 (75,3)
• No 66 (12,7) 456 (87,4)
Respiratory insufficiency; n (%) 0,01
• Yes 8 (57,1) 6 (42,9)
• No 79 (13,6) 503 (86,4)
Transitory psychotic syndrome; n (%) 0,34
• Yes 5 (25) 15 (75)
• No 84 (14) 511 (86)
Mortality after 30 days; n (%) 0,11
• Yes 6 (26) 17 (74)
• o 83 (14) 508 (86)
BMI Body Mass Index, PAOD peripheral arterial obstructive disease, COPD
chronic obstructive pulmonary disease, IABP intraaortic balloon pulsation,
ICU intensive care unit, Periop. MI perioperative myocardial infarction, RBC red
blood concentrate.
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[26]. But the trials included in these two meta-analyses
were performed with different antibiotic regimens and
were pooled for the analyses. Therefore, they relay on
studies comparing different antibiotic regimens [4].
Fowler et al. identified and validated a model (n = 331429
CABG patients) that identify patients undergoing cardiac
surgery who are at high risk for major infection (Age, BMI,
Diabetes, Renal failure, Congestive heart failure, Peripheral
vascular disease, Female gender, Chronic lung disease,
Cardiogenic shock, Myocardial infarction, Concomitant
surgery, Perfusion time 100 to 300 minutes, and Intra-Table 5 Subgroup analyses
Risk factors Group I (56 h) Group II (32 h) p-value
Female 23,5% 22,3% 0,82
Age > 80 years 23,7% 23,7% 1,00
PAOD 16,9% 25,3% 0,20
Operating time 240 min 22,8% 20,3% 0,63
ICU duration < 3 days 20,5% 21,0% 1,00
Transfusion of > 5 RBC 26,5% 29,6% 0,91
Respiratory insufficiency 62,5% 66,7% 1,00
PAOD peripheral arterial obstructive disease, ICU intensive care unit, RBC red
blood concentrate.
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our findings. These high-risk patients may be targeted
for perioperative intervention strategies to reduce rates
of major infection [15]. On the basis of these findings,
we intend a prospective randomized trial calculating the
duration of perioperative antibiotic prophylaxis depend-
ing on this individualized scoring system for cardiac
surgery patients (single dose versus 24 hours). Limita-
tions of this study are the following facts: First, we per-
formed a retrospective observational single-center study
over a time period of one year with consecutive patients
rather than a prospective randomised multicenter trial.
Second, the small number of patients (n = 615) did not
provide sufficiently the power to analyse the effect of re-
ducing the perioperative antibiotic prophylaxis.
Conclusions
On the basis of the international literature, the different
guidelines and the results obtained in this observational
study, reducing the duration of perioperative antibiotic
prophylaxis from 56 h to 32 h in adult cardiac surgery
patients does not increase the rate of surgical site infec-
tion, nosocomial infection and the mortality rate, but it
contributes to reduce antibiotic resistance and health
care costs.
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